<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663767</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-797-222</org_study_id>
    <secondary_id>C4411009</secondary_id>
    <nct_id>NCT00663767</nct_id>
  </id_info>
  <brief_title>A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction</brief_title>
  <official_title>A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group Analgesic Efficacy Trial of Oral ARRY-371797 in Subjects Undergoing Third Molar Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      This is a Phase 2 study designed to test the ability of investigational study drug&#xD;
      ARRY-371797 to reduce pain in a postoperative pain model (third molar extraction), and to&#xD;
      further evaluate the drug's safety. Approximately 250 subjects from the US will be enrolled&#xD;
      in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2008</start_date>
  <completion_date type="Actual">June 20, 2008</completion_date>
  <primary_completion_date type="Actual">June 20, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the efficacy of the study drug dosed postoperatively in terms of total pain relief (TOTPAR).</measure>
    <time_frame>6 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, electrocardiograms and vital signs.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the efficacy of the study drug (versus placebo and celecoxib) in terms of pain relief measurements [including TOTPAR, total pain intensity (TPI) and time to rescue medication].</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Dental Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, ARRY-371797</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARRY-371797, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARRY-371797</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib, Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib, ARRY-371797</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo; oral</intervention_name>
    <description>dose 1, dose 2</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo; oral</intervention_name>
    <description>dose 1</description>
    <arm_group_label>Placebo, ARRY-371797</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-371797, p38 inhibitor; oral</intervention_name>
    <description>dose 1: multiple dose levels</description>
    <arm_group_label>ARRY-371797, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-371797, p38 inhibitor; oral</intervention_name>
    <description>dose 1: multiple dose levels; dose 2</description>
    <arm_group_label>ARRY-371797</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib, COX-2 inhibitor; oral</intervention_name>
    <description>dose 1</description>
    <arm_group_label>Celecoxib, ARRY-371797</arm_group_label>
    <arm_group_label>Celecoxib, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo; oral</intervention_name>
    <description>dose 2</description>
    <arm_group_label>ARRY-371797, Placebo</arm_group_label>
    <arm_group_label>Celecoxib, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-371797, p38 inhibitor; oral</intervention_name>
    <description>dose 2</description>
    <arm_group_label>Celecoxib, ARRY-371797</arm_group_label>
    <arm_group_label>Placebo, ARRY-371797</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for outpatient oral surgical procedure to remove 3 or more third molars, at&#xD;
             least 1 of which is mandibular and fully or partially impacted by bone.&#xD;
&#xD;
          -  Females of childbearing potential must be willing to use an acceptable method of&#xD;
             contraception within 14 days prior to first dose of study drug until the completion of&#xD;
             the follow-up procedures.&#xD;
&#xD;
          -  Body weight &gt;50 kg (110 lbs).&#xD;
&#xD;
          -  Good health determined by medical history, physical examination, vital signs and&#xD;
             clinical laboratory results of non-clinical significance.&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant dermatologic, hematological, renal,&#xD;
             endocrine (e.g. poorly controlled diabetes), pulmonary, gastrointestinal,&#xD;
             cardiovascular, hepatic, neurologic, ophthalmologic, or allergic disease (including&#xD;
             clinically significant drug allergies that could impact the conduct of this study, but&#xD;
             excluding untreated, asymptomatic, seasonal allergies at time of study drug dosing).&#xD;
&#xD;
          -  Positive urine drug screen within 28 days prior to first dose of study drug.&#xD;
&#xD;
          -  Use of prohibited prescription drugs, or grapefruit juice within 7 days of first dose&#xD;
             of study drug; prohibited medications are defined as nonsteroidal and steroidal&#xD;
             antiinflammatory drugs, analgesics including opioids (except low dose aspirin for&#xD;
             myocardial infarction prophylaxis), P450 CYP3A substrates or inhibitors (strong or&#xD;
             moderate).&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Phase I Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://medicine.iupui.edu/flockhart/table.htm</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <disposition_first_submitted>December 9, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>December 9, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 11, 2009</disposition_first_posted>
  <last_update_submitted>February 7, 2021</last_update_submitted>
  <last_update_submitted_qc>February 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toothache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

